EUVIMEDEUVIMED entdecken
Crossref

Multinutrients as Adjunctive Treatment for Bipolar Disorder: A randomized-controlled trial feasibility study

Lewis Mehl-Madrona, MD, PhD, Patrick McFarlane, LCSW, PMH-NP, FNP, Astha Kakkad MD, MSPH, Samreen Fathima, BDS, MPH

Etuaptmumk: The Journal of Two-Eyed Seeing · 2024

DOI: 10.59401/ej.v5i1.19 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Etuaptmumk: The Journal of Two-Eyed Seeing, 2024. Verfasst von Lewis Mehl-Madrona und 11 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

An open label trial showed reduction in symptoms from a comprehensive micronutrient supplement in combination with Fish Oil for adults diagnosed with bipolar disorder.

Methods

A double blinded, randomized, controlled feasibility trial explored the parameters necessary to mount a larger trial. We randomized in a 3:2 ratio to multinutrients or Placebo. We recruited patients diagnosed with bipolar disorder from a family medicine residency clinic. Diagnoses were confirmed via psychiatric interview. The primary outcome measure was change on a composite z-score of the clinical global impressions scale (CGI), the UKU Side Effects Scale, and medication doses.

Results

A total of 69 patients were randomized and data was analyzed for 49 patients. The mean difference of the composite z-score for the multinutrient group was 0.63 (SD; 0.25) and for the Placebo Group 0.47 (SD=0.22). Independent samples t-testing gave a t-score for that difference of 2.429 (p = 0.019; ES = 0.437; 95% CI = -0.556 to -0.053). Significantly more patients in the multinutrient group improved on the CGI (p = 0.04; OR = 4.0; 52% responders vs. 22% in the Placebo Group). All patients improved on the secondary measures with inter-group differences favoring the multinutrient group that did not reach statistical significance. The only adverse events occurring more among the multinutrient group were nausea and loose stools but these were not statistically significant between groups.

Conclusions

Multinutrients show promise for adjunctive treatment of bipolar disorder. We observed benefits for patients from closer surveillance, medication adjustment (mostly reduction), and increased human contact.

Zitieren

APA

Mehl-Madrona, L., MD, PhD, McFarlane, P., LCSW, PMH-NP, FNP, MD, A. K., MSPH, Fathima, S., BDS, & MPH (2024). Multinutrients as Adjunctive Treatment for Bipolar Disorder: A randomized-controlled trial feasibility study. Etuaptmumk: The Journal of Two-Eyed Seeing. https://doi.org/10.59401/ej.v5i1.19

Vancouver

Mehl-Madrona L, MD, PhD, McFarlane P, LCSW, PMH-NP, et al. Multinutrients as Adjunctive Treatment for Bipolar Disorder: A randomized-controlled trial feasibility study. Etuaptmumk: The Journal of Two-Eyed Seeing. 2024. doi:10.59401/ej.v5i1.19

BibTeX
@article{MehlMadrona2024,
  author = {Mehl-Madrona, Lewis and MD and PhD and McFarlane, Patrick and LCSW and PMH-NP and FNP and MD, Astha Kakkad and MSPH and Fathima, Samreen and BDS and MPH},
  title = {Multinutrients as Adjunctive Treatment for Bipolar Disorder: A randomized-controlled trial feasibility study},
  journal = {Etuaptmumk: The Journal of Two-Eyed Seeing},
  year = {2024},
  doi = {10.59401/ej.v5i1.19}
}
Kostenlos starten →